Skip Navigation

R.A. Session II, Taysha Gene Therapies

CEO 1835


R.A. Session II founded the biotech startup Taysha Gene Therapies in 2019, in partnership with UT Southwestern Medical Center. Created to develop therapies that treat central nervous system diseases primarily affecting children, the startup has received an infusion of capital from investors. This November on CEO, Session joins host Lee Cullum to discuss Taysha’s future and its plans to develop programs targeting numerous debilitating diseases. Though a near-term loss is expected, Session outlines the company’s path aimed toward long-term success. You can stream the episode above or:

Watch this episode on KERA TV:

Friday, November 20 at 7:30pm
Sunday, November 22 at 10:30am
Monday, November 23 at 10pm

Listen to this episode on KERA FM:

Sunday, December 6 at 5pm


For more information on patients battling central nervous system diseases visit: